Page last updated: 2024-11-07

becatecarin

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

Becatecarin is a novel, orally administered, small-molecule drug that targets the serotonin 3 (5-HT3) receptor. It is being investigated for the treatment of chemotherapy-induced nausea and vomiting (CINV). Becatecarin was synthesized through a series of chemical reactions involving various organic compounds and reagents. The exact synthesis pathway is proprietary information held by the company developing it. Becatecarin is believed to act as an antagonist at the 5-HT3 receptor, which is known to play a critical role in the development of CINV. By blocking this receptor, becatecarin is expected to prevent the activation of nerve pathways that lead to nausea and vomiting. Becatecarin is being studied because it has the potential to offer a novel and effective treatment option for CINV, which can significantly impact the quality of life of cancer patients. Its oral administration and targeted mechanism of action make it a promising candidate compared to existing antiemetic therapies. Research is ongoing to evaluate its safety, efficacy, and optimal dosage in various clinical settings.'

becatecarin: a rebeccamycin deriviative [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID101524
CHEMBL ID2107313
SCHEMBL ID5953787
MeSH IDM0246034

Synonyms (37)

Synonym
bmy 27557
nsc-655649
119673-08-4
bms-181176
D03220
becatecarin (usan/inn)
becatecarin
xl 119
1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-o-methyl-beta-d-glucopyranosyl)-5h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6h)-dione
5h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6h)-dione, 1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-o-methyl-beta-d-glucopyranosyl)-
xl119 ,
unii-a60x6mbu6g
bms 181176
bmy-27557
1,11-dichloro-6-(2-(diethylamino)ethyl)-12-(4-o-methyl-beta-d-glucopyranosyl)-12,13-dihydro-5h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6h)-dione
a60x6mbu6g ,
becatecarin [usan:inn]
nsc 655649
xl-119
CHEMBL2107313
deae-rebeccamycin
SCHEMBL5953787
becatecarin [mart.]
5h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6h)-dione, 1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-o-methyl-.beta.-d-glucopyranosyl)-
6-(2-(diethylamino)ethyl)-rebeccamycin
becatecarin [inn]
1,11-dichloro-6-(2-(diethylamino)ethyl)-12,13-dihydro-12-(4-o-methyl-.beta.-d-glucopyranosyl)-5h-indolo(2,3-a)pyrrolo(3,4-c)carbazole-5,7(6h)-dione
becatecarin [who-dd]
becatecarin [usan]
nsc 655649; xl 119;bms 181176; bmy 27557
1,11-dichloro-6-(2-(diethylamino)ethyl)-12-((2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxytetrahydro-2h-pyran-2-yl)-12,13-dihydro-5h-indolo[2,3-a]pyrrolo[3,4-c]carbazole-5,7(6h)-dione
DB06362
Q27273671
5,21-dichloro-13-[2-(diethylamino)ethyl]-3-[(2r,3r,4r,5s,6r)-3,4-dihydroxy-6-(hydroxymethyl)-5-methoxyoxan-2-yl]-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4(9),5,7,10,15,17(22),18,20-nonaene-12,14-dione
6-n-[2-(diethylamino)ethyl]rebeccamycin
DTXSID60869635
AKOS040755287

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" We performed a phase I trial to determine the maximum-tolerated dose (MTD) of rebeccamycin analog when given on a daily x 5 schedule repeated every 3 weeks, characterize the toxicity profile using this schedule, observe patients for antitumor response, and determine the pharmacokinetics of the agent and pharmacodynamic interactions."( Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
Dowlati, A; Gerson, SL; Hoppel, CL; Ingalls, ST; Ivy, P; Li, X; Majka, S; Remick, SC; Sedransk, N; Spiro, T, 2001
)
0.31
" Pharmacokinetic analysis revealed a three-compartmental model of drug elimination and a long terminal half-life (154 +/- 55 hours)."( Phase I clinical and pharmacokinetic study of rebeccamycin analog NSC 655649 given daily for five consecutive days.
Dowlati, A; Gerson, SL; Hoppel, CL; Ingalls, ST; Ivy, P; Li, X; Majka, S; Remick, SC; Sedransk, N; Spiro, T, 2001
)
0.31
"To assess the feasibility of administering NSC 655649, a water-soluble, rebeccamycin analog with topoisomerase inhibitory properties, as a brief intravenous (IV) infusion once every 3 weeks and to determine the maximum-tolerated dose (MTD) of NSC 655649, characterize its pharmacokinetic behavior, and seek preliminary evidence of antitumor activity."( Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Aylesworth, C; Campbell, E; Eckhardt, SG; Felton, S; Hammond, L; Hidalgo, M; Kuhn, J; Patnaik, A; Rizzo, J; Rowinsky, EK; Schwartz, G; Tolcher, AW; Weiss, G, 2001
)
0.31
" Plasma and urine were sampled to characterize the pharmacokinetic and excretory behavior of NSC 655649."( Phase I and pharmacokinetic study of NSC 655649, a rebeccamycin analog with topoisomerase inhibitory properties.
Aylesworth, C; Campbell, E; Eckhardt, SG; Felton, S; Hammond, L; Hidalgo, M; Kuhn, J; Patnaik, A; Rizzo, J; Rowinsky, EK; Schwartz, G; Tolcher, AW; Weiss, G, 2001
)
0.31
"NSC 655649 was given in both single- and multiple-dose formats, to characterize maximum tolerated dose (MTD), toxicity, and pharmacokinetic profile."( Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.
Alberti, D; Arzoomanian, R; Binger, K; Cleary, J; Dresen, A; Feierabend, C; Marnoccha, R; Merchant, J; Thomas, J; Tutsch, K; Wilding, G, 2002
)
0.31
" Plasma and urine were sampled to assess the pharmacokinetic and excretory characteristics of NSC 655649."( Phase I clinical and pharmacokinetic study of NSC 655649, a rebeccamycin analogue, given in both single-dose and multiple-dose formats.
Alberti, D; Arzoomanian, R; Binger, K; Cleary, J; Dresen, A; Feierabend, C; Marnoccha, R; Merchant, J; Thomas, J; Tutsch, K; Wilding, G, 2002
)
0.31
" Major pharmacokinetic interactions between NSC 655649 and CDDP were not apparent."( Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Berg, K; Forero, L; Forouzesh, B; Goetz, A; Hammond, LA; Kuhn, JG; Ochoa-Bayona, JL; Ricart, AD; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2005
)
0.33
" Neither pharmacokinetic interactions between the agents nor sequence-dependent toxicologic or pharmacokinetic effects were apparent."( Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Berg, K; Forero, L; Forouzesh, B; Goetz, A; Hammond, LA; Kuhn, JG; Ochoa-Bayona, JL; Ricart, AD; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2005
)
0.33
" Secondary endpoints were survival and pharmacokinetic characterization."( Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
Brell, J; Chak, A; Dowlati, A; Fu, P; Hoppel, CL; Ingalls, S; Ivy, P; Krishnamurthi, S; Posey, J; Ramanathan, RK; Rath, L; Remick, SC, 2009
)
0.35
" The pharmacokinetic profile of this trial closely resembles those of prior phase I trials."( Phase II and pharmacokinetic trial of rebeccamycin analog in advanced biliary cancers.
Brell, J; Chak, A; Dowlati, A; Fu, P; Hoppel, CL; Ingalls, S; Ivy, P; Krishnamurthi, S; Posey, J; Ramanathan, RK; Rath, L; Remick, SC, 2009
)
0.35

Dosage Studied

ExcerptRelevanceReference
" Sequential dose escalation of NSC 655649 or CDDP resulted in three dosage permutations of NSC 655649/CDDP: 440/50, 550/50, and 440/75 mg/m2."( Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors.
Berg, K; Forero, L; Forouzesh, B; Goetz, A; Hammond, LA; Kuhn, JG; Ochoa-Bayona, JL; Ricart, AD; Rowinsky, EK; Takimoto, CH; Tolcher, AW, 2005
)
0.33
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (17)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (5.88)18.7374
1990's1 (5.88)18.2507
2000's14 (82.35)29.6817
2010's1 (5.88)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 19.83

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index19.83 (24.57)
Research Supply Index3.40 (2.92)
Research Growth Index5.60 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (19.83)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials11 (61.11%)5.53%
Reviews2 (11.11%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (27.78%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]